Shockwave Medical, Inc.·4

Feb 16, 8:02 PM ET

Godshall Douglas Evan 4

4 · Shockwave Medical, Inc. · Filed Feb 16, 2024

Insider Transaction Report

Form 4
Period: 2024-02-15
Godshall Douglas Evan
DirectorPresident & CEO
Transactions
  • Sale

    Common Stock

    2024-02-15$233.54/sh200$46,708164,193 total
  • Sale

    Common Stock

    2024-02-15$235.21/sh600$141,126163,593 total
  • Sale

    Common Stock

    2024-02-15$236.13/sh831$196,224162,762 total
  • Sale

    Common Stock

    2024-02-15$230.86/sh2,800$646,408167,172 total
  • Sale

    Common Stock

    2024-02-15$232.74/sh792$184,330164,393 total
  • Exercise/Conversion

    Common Stock

    2024-02-15$3.42/sh+10,000$34,160172,762 total
  • Sale

    Common Stock

    2024-02-15$231.74/sh1,987$460,467165,185 total
  • Sale

    Common Stock

    2024-02-15$228.28/sh560$127,837172,202 total
  • Sale

    Common Stock

    2024-02-15$229.82/sh2,230$512,499169,972 total
  • Exercise/Conversion

    Stock Option

    2024-02-1510,000294,799 total
    Exercise: $3.42Exp: 2027-05-09Common Stock (10,000 underlying)
Footnotes (10)
  • [F1]All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/25/2023.
  • [F10]Fully vested.
  • [F2]The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $227.95 to $228.82. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  • [F3]The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $229.12 to $230.08. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  • [F4]The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $230.32 to $231.24. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  • [F5]The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $231.35 to $232.18. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  • [F6]The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $232.37 to $233.25. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  • [F7]All reported securities were sold at a price of $233.54.
  • [F8]The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $234.91 to $235.53. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  • [F9]The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $235.99 to $236.51. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Documents

1 file
  • 4
    wk-form4_1708131730.xmlPrimary

    FORM 4